Microbiome in Immunotherapy naïve NSCLC Patients Receiving PD-1/L1 Blockade (MIP_NSCLC)
This phase IV study is hoping to determine if examining the microbiome in non-small cell lung cancer, immunotherapy naive participants can predict the effectiveness of immunotherapy treatment as well as determine ahead of time adverse events and their severity. In addition, the investigator will look into microbiome changing modifiers.
Checked against the public recordLast updated Dec 11, 2023 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- Jun Zhang, MD, PhD
- Interventions being studied
- Diagnostic Test: Microbiome
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Must have tumor tissue biopsy-proven to be NSCLC * Must have a target lesion to evaluate treatment response * Immunotherapy naïve metastatic/advanced/recurrent NSCLC patients * Will receive single agent anti-PD-1/PD-L1 therapy (e.g. pembrolizumab, nivolumab, atezolizumab, avelumab or durvalumab, etc.). Patients can be on other interventional trial if they will be receiving single agent anti-PD-1/PD-L1 Exclusion Criteria: * Prior treatment with any forms of cancer immunotherapy * Not competent to make medical decision, noncommunicative or noncompliant per treating physician's judgement * Not English-speaking * Patients that are pregnant * Prisoners * Students and employees * Psychiatric illness/social situations that would limit compliance with study requirements
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- The University of Kansas Cancer Center (KUCC)Fairway, Kansas
- The University of Kansas Medical CenterKansas City, Kansas
- The University of Kansas Cancer Center, Westwood CampusKansas City, Kansas
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Dec 11, 2023. Always confirm current availability with the study team.